UHS Earnings

UHS reported its earnings on 2026-04-27, showcasing a revenue of 4.50B against an estimate of 4.37B, resulting in a 2.86% surprise. The EPS was 5.62, surpassing the expected 5.29 by 6.24%. The stock experienced a -9.45% price change on the earnings day and a -6.97% change over the next five days, reflecting market reactions to the results.

Following UHS's earnings announcement on 2026-04-27, the stock price moved by -9.45% on the day of the release. Over the subsequent five days, it saw a -6.97% change. Historically, UHS's stock price tends to shift by an average of 0.33% in the 10 days leading up to earnings and 0.76% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate UHS's annual revenue to reach 4.49B, while the EPS is projected at 5.84. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between UHS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, UHS's stock price typically moves by 0.33% in the 10 days before its earnings and 0.76% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 5.84 and revenue of 4.49B.

The earnings call summary provides mixed signals. While there are positive aspects such as revenue growth and operational improvements, there are also concerns about adverse impacts from health insurance exchanges, staffing regulations, and the expected operating loss for a new hospital. The Q&A session highlights uncertainties in Medicaid payments and payer mix changes, but also notes positive trends in behavioral health demand and outpatient growth. Overall, the balance of positive and negative factors suggests a neutral stock price movement over the next two weeks.